Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER⁺HER2^-Rb wild-type and knock-down in breast cancer cell lines.

ABSTRACT:

Background

Breast cancer (BC) is the second most common type of cancer worldwide. Among targeted therapies for Hormone Receptor-positive (HR⁺) and Human Epidermal growth factor Receptor 2-negative (HER2^-) BC, the Cyclin-Dependent Kinases (CDK4/6) are targeted by inhibitors such as Ribociclib (Rib); however, resistance to CDK4/6 inhibitors frequently develops. The aim of this work is to assess in vitro activity of Rib and Everolimus (Eve) in HR⁺HER2^- MCF-7 and HR^-HER2^-BT-549 BC cell lines.

Methods

HR⁺HER2^- MCF-7 and HR^-HER2^- BT-549 BC cell lines were treated with increasing concentration of Rib and Eve (up to 80 μg/mL) for 48-72 h. Subsequently, HR⁺HER2

SUBMITTER: Marinelli O 

PROVIDER: S-EPMC7678099 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature